Development of KSQ-4279 as a first-in-class USP1 inhibitor for the treatment of BRCA-deficient cancers

Louise Cadzow, J. Brenneman, Richard Sullivan, H. Liu, Sol Shenker, Michael McGuire, Paula Grasberger, Kerstin W. Sinkevicius, Nafeeza Hafeez, Gavin Histen, Edmond Chipumuro, Julie A. Hixon, Elizabeth A. Krall, Shawn Cogan, Johannes H.W. de Wilt, Michael R. Schlabach, Frank Stegmeier, Andrew Olaharski, Andrew A. Wylie